Published Tuesday in the journal Cell Metabolism, the study is the latest research to come out of the laboratory of Daniel Drucker, the Canadian scientist renowned for his pioneering research into glucagon-like peptide-1 receptor agonists, or GLP-1s
If cost is a concern, its smart to check your insurance coverage before committing to a pill
Reality check: Most patients dont want to exercise when already exhausted from rapid weight loss
Overall, the study supports current guideline flexibility, indicating that both GLP-1RAs and SGLT2 inhibitors provide broadly similar cardiovascular protection
Even siblings have their secrets
Both are linked to brighter, healthier skin, but they work in very different ways